Research programme: CEACAM6 monoclonal antibody - MontigenAlternative Names: CD66c; CEACAM6; CEACAM6 monoclonal antibody research programme - Montigen Pharmaceuticals
Latest Information Update: 14 Feb 2006
At a glance
- Originator Montigen
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Feb 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 16 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)